Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | MEN1 | O00255 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | RGS12 | O14924 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.33 |
| ▸ | BLM | P54132 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17873661 | 1.00 | EGFR (0.43) | EGFRERBB2GABRA1GABRG2GABRB3 | |
| SCHEMBL17884073 | 1.00 | EGFR (0.43) | EGFRERBB2GABRA1GABRG2GABRB3 | |
| SCHEMBL13681565 | 0.84 | EGFR (0.46) | EGFRERBB2GABRA1GABRG2GABRB3 | |
| SCHEMBL12715617 | 0.81 | GABRA1 (0.45) | EGFRERBB2GABRA1GABRG2GABRB3 | |
| SCHEMBL12715623 | 0.81 | GABRA1 (0.45) | EGFRERBB2GABRA1GABRG2GABRB3 | |
| SCHEMBL13681521 | 0.78 | EGFR (0.41) | EGFRERBB2GABRA1GABRG2GABRB3 | |
| SCHEMBL21056104 | 0.78 | GABRA1 (0.49) | EGFRERBB2GABRA1GABRG2GABRB3 | |
| SCHEMBL21134491 | 0.78 | GABRA1 (0.49) | EGFRERBB2GABRA1GABRG2GABRB3 | |
| SCHEMBL21056103 | 0.78 | GABRA1 (0.49) | EGFRERBB2GABRA1GABRG2GABRB3 | |
| SCHEMBL14006385 | 0.74 | EGFR (0.49) | EGFRERBB2GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4302830-A2 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-3960735-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230043136-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2023-02-09 | — | — | US | disclosed |
| US-20230043136-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2023-02-09 | — | — | US | disclosed |
| US-11304948-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3960735-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20200360383-A1 | Quinazoline Compounds | GILEAD SCIENCES, INC. | 2020-11-19 | — | — | US | disclosed |
| US-10548898-B2 | Quinazoline compounds | GILEAD SCIENCES INC. (US) | 2020-02-04 | — | — | US | disclosed |
| EP-3521282-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190134035-A1 | Quinazoline Compounds | GILEAD SCIENCES, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20170354656-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2017-12-14 | — | — | US | disclosed |
| EP-3237398-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9730936-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730936-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730936-B2 | Quinazoline compounds | GILEAD SCIENCES, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2016-09-01 | — | — | US | disclosed |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2016-09-01 | — | — | US | disclosed |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2016-09-01 | — | — | US | disclosed |
| WO-2016105564-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105564-A1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304948-B2 | Quinazoline compounds | TTBK1, TTBK2, MAPT | EGFR 4658/4885ERBB2 3989/4885GABRA1 2037/4885 |
| US-20190134035-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | EGFR 4658/4885ERBB2 3989/4885GABRA1 2037/4885 |
| US-20160250215-A1 | QUINAZOLINE COMPOUNDS | TTBK1, TTBK2, MAPT | EGFR 4658/4885ERBB2 3989/4885GABRA1 2037/4885 |
| US-20200360383-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | EGFR 4658/4885ERBB2 3989/4885GABRA1 2037/4885 |
| US-20230043136-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | EGFR 4658/4885ERBB2 3989/4885GABRA1 2037/4885 |
| US-10548898-B2 | Quinazoline compounds | TTBK1, TTBK2, MAPT | EGFR 4658/4885ERBB2 3989/4885GABRA1 2037/4885 |
| US-20170354656-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | EGFR 4658/4885ERBB2 3989/4885GABRA1 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.